218 related articles for article (PubMed ID: 34084103)
21. Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial.
Lu S; Chen Z; Hu C; Zhang J; Chen Y; Song Y; Zhao Q; Fan Y; Wu G; Ma Z; Fang J; Yu Q; Liu Z
J Thorac Oncol; 2018 Nov; 13(11):1743-1749. PubMed ID: 30017831
[TBL] [Abstract][Full Text] [Related]
22. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
23. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].
Zhang YF; Yu YF; Lu S
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1544-8. PubMed ID: 19953882
[TBL] [Abstract][Full Text] [Related]
25. Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute.
Yu WX; Tang LN; Lin F; Yao Y; Shen Z
Oncol Lett; 2014 Nov; 8(5):2243-2248. PubMed ID: 25289103
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
[TBL] [Abstract][Full Text] [Related]
28. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
Petrylak DP; Tagawa ST; Kohli M; Eisen A; Canil C; Sridhar SS; Spira A; Yu EY; Burke JM; Shaffer D; Pan CX; Kim JJ; Aragon-Ching JB; Quinn DI; Vogelzang NJ; Tang S; Zhang H; Cavanaugh CT; Gao L; Kauh JS; Walgren RA; Chi KN
J Clin Oncol; 2016 May; 34(13):1500-9. PubMed ID: 26926681
[TBL] [Abstract][Full Text] [Related]
31. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
32. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
33. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma.
Sun XS; Wang XH; Liu SL; Luo DH; Sun R; Liu LT; Guo SS; Chen QY; Tang LQ; Mai HQ
Front Oncol; 2020; 10():1295. PubMed ID: 32850404
[No Abstract] [Full Text] [Related]
35. Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.
Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Liu G; Yao W
Front Oncol; 2022; 12():922127. PubMed ID: 35912272
[TBL] [Abstract][Full Text] [Related]
36. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Belani CP; Fossella F
Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
38. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination
Wu L; Deng C; Zhang H; Weng J; Wu Y; Zeng S; Tang T; Cao P; Qiu B; Zhang L; Duan H; Zhang B; Zhang D; Zhang T; Hu C
Front Oncol; 2021; 11():769037. PubMed ID: 34976813
[TBL] [Abstract][Full Text] [Related]
40. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
